

Review

Not peer-reviewed version

Mutant IDH in Gliomas: Role in Cancer and Treatment Options

[Georgios Solomou](#)[†], [Alina Finch](#)[†], Asim Asghar, [Chiara Bardella](#)^{*}

Posted Date: 18 April 2023

doi: 10.20944/preprints202304.0478.v1

Keywords: isocitrate dehydrogenase, cancer metabolism, hydroxyglutarate, gliomas, oncometabolites



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Mutant IDH in Gliomas: Role in Cancer and Treatment Options

Georgios Solomou ^{1,2,3,†}, Alina Finch ^{1,†}, Asim Asghar ¹ and Chiara Bardella ^{1,*}

¹ Institute of Cancer Genomic Sciences, University of Birmingham, Birmingham, UK.

² Division of Academic Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK

³ Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK

* Correspondence: c.bardella@bham.ac.uk

† These authors have contributed equally

Abstract: Altered metabolism is a common feature of many cancers and in some cases is a consequence of mutation in metabolic genes, such as the ones involved in Krebs cycle. Isocitrate dehydrogenase (*IDH*) gene is mutated in many gliomas and other cancers. Physiologically IDH converts isocitrate to α -ketoglutarate (α KG), but when mutated, IDH reduces α KG to D2-hydroxyglutarate (D2-HG). D2-HG accumulates at high levels in IDH mutant cancers, and in the last decade, a massive effort has been done to develop small inhibitors targeting mutant IDH. In this review, we summarize current knowledge about the cellular and molecular consequences of IDH mutations, and the therapeutic approaches developed to target IDH mutant tumours, with a focus on gliomas.

Keywords: isocitrate dehydrogenase; cancer metabolism; hydroxyglutarate; gliomas; oncometabolites

1. Introduction

The isocitrate dehydrogenase (IDH) family includes three enzymes, IDH1, IDH2, and IDH3 that are ubiquitously expressed in human cells. Although all these enzymes catalyse the same chemical reaction, i.e. the oxidative decarboxylation of isocitrate (ICT) to α -ketoglutarate (α KG), each enzyme has unique biological properties. IDH1 is localized to the cytoplasm and peroxisomes of the cells, where it has a role in the glucose and lipid metabolisms and protects against reactive oxygen species (ROS) [1] [2] [3] [4]. IDH2 and IDH3 are both found in the mitochondrial matrix [5], where IDH2 exerts its regulatory function on the tricarboxylic acid (TCA) cycle and protects against oxidative stress [6], while IDH3 functions as a central enzyme of the TCA cycle [6]. IDH1 and IDH2 are homodimers, while IDH3 is a heterotetrameric protein, composed by two catalytic α subunits required for ICT binding, a β subunit, which has a structural role to facilitate the enzyme subunits assembly, and the γ subunit, that through binding of citrate and ADP, functions as an allosteric modulator [7] [8]. The chemical reaction catalyzed by IDH1 and IDH2 is reversible and requires binding of nicotinamide adenine dinucleotide phosphate (NADP⁺) as co-factor, which is converted into NADPH [9], while the chemical reaction of IDH3 is irreversible, and involves binding of NAD⁺, which is reduced to NADH. Moreover, unlike IDH1 and 2, the chemical reaction catalyzed by IDH3 is tightly regulated by substrate availability and allosteric effectors (citrate, ICT, adenosine 5'-diphosphate (ADP), nicotinamide adenine dinucleotide (NAD⁺), Mg²⁺/Mn²⁺ and Ca²⁺) product inhibition (NADH NADPH and α KG) and competitive feedback inhibition (adenosine 5'-triphosphate (ATP)) [10] to avoid an unnecessary usage of ICT and increase of α KG.

In the last decades recurrent somatic mutations in *IDH1* and *IDH2* genes have been identified in many cancers, such as low grade gliomas (LGG) (>70 %), secondary glioblastoma (diffuse astrocytoma, WHO CNS grade 4 according to the the 2021 guidelines) (55%-88%) [11–16], chondrosarcoma (56%) [17], intrahepatic cholangiocarcinoma (23%) [18], acute myeloid leukaemia (16%), as well as to

a lower extent, myelodysplastic syndrome and angioimmunoblastic T-cell lymphoma [19], and other solid tumours.

In contrast to *IDH1* and *IDH2*, no tumour-associated mutations for any of the *IDH3* genes (*IDH3A*, *IDH3B* and *IDH3G*) have been reported [20].

IDH changes are missense mutations, which affect predominantly to the arginine residues R132 in *IDH1*, R172 and R140 in *IDH2* [11]. These arginine residues are crucial for the recognition of isocitrate. In the mutant *IDH1* the highly positively charged arginine residue at position 132 is replaced by lower polarity amino acids such as histidine, cysteine, glycine or lysine. This missense mutation intervenes with the alpha and beta carboxyl sites of isocitrate [21] [22]. This results in a weak affinity for isocitrate in addition to raised NADPH levels, since less is going to be used as a co-factor for a forward reaction. IDH mutations are monoallelic changes, which result in an enzyme composed by a wildtype and mutant monomers. Consequently, in IDH mutant cells, the wildtype part of the dimer leads to the conversion of isocitrate to α -KG producing NADPH, whereas the mutant monomer, by using NADPH as a co-factor, converts α -KG to the D2-enantiomer of hydroxyglutarate (D2-HG; the L2- enantiomer, L2-HG, is not significantly produced), exhibiting a neomorphic activity [23]. Consequently, in IDH-mutant tumours, D2-HG accumulates to millimolar concentrations, while due to the enzymatic loss of function, the α KG decreases [24] [25]. Beside its role as a biomarker in IDH-mutant malignancies, D2-HG is thought to be an oncometabolite [24], mainly for its role in competitively inhibits the enzymatic activities of α KG-dependent dioxygenases, such as histone lysine demethylases (KDMs), or ten-eleven translocation methylcytosine (TET) family enzymes [26] [27]. Consequently, IDH mutations result in hypermethylation of DNA and histones, which is considered one of the leading mechanism of tumorigenesis.

IDH1 and *IDH2* mutations appear to be mutually exclusive [28] [29] [30], with some rare exceptions [13] [28] [19]. Interestingly, the nature of the various IDH substitutions differ between the cancer types, such as *IDH1* is more frequently mutated in solid tumors, while *IDH2* is mainly mutated in some blood cancers. Moreover, specific IDH variants seem to be more frequent in particular type of tumors. For instance, in LGG, the majority of IDH mutations occur in the *IDH1* gene, which is mainly converted to the R132H variant. In chondrosarcoma and cholangiocarcinoma *IDH1* is mostly frequently mutated and specifically to the variant R132C [31]. Interestingly, patients harbouring *IDH1*^{R132H} mutated tumours have lower levels of genome-wide DNA-methylation, an increased gene expression, and a worst prognosis, compared to tumours with other *IDH1/2* mutations [31].

The reason for the tissue specificity of the various IDH mutations in different cancers is still not clear. However, it looks like that specific IDH mutations differ in their capacity of producing D2-HG [32] [33]. For instance, *IDH1*^{R132H} has a relatively low capacity to produce D2-HG compared to other mutations, such as *IDH1*^{R132C}, which is highly more efficient [32] [33]. Potentially each tumour types may require a certain amount of D2-HG to initiate tumor formation, as different levels of D2-HG might be required to impact on a tissue specific enzymes/pathways driving cancer initiation and progression. For instance, not all α KG-dependent dioxygenases are equally well inhibited by the D2-HG, and some of them, such as TET2 enzymes require high levels of D2-HG to be inhibited [34].

It is well recognized that IDH mutations have a biological impact both intracellularly, as well as part of the tumour microenvironment, favouring tumour formation and recurrence, and in last decades many functional studies have been focused in understanding the molecular mechanisms responsible for the formation IDH-mutant tumour. These studies mainly focus on the functional significance of the D2-HG accumulation, but despite many efforts, the biological mechanism driving tumour formation are not completely clear. Taking into consideration that current therapies fail to demonstrate improvement in outcomes, IDH induced biochemical alterations should be adequately understood and assessed as potential target. Here we summarize the current knowledge of IDH-mutated human malignancies, with a focus on glioma, discussing the oncogenic role of mutant IDH in tumour formation and the therapeutic opportunities.

2. The Oncogenic Role of Mutant IDH in Tumour Formation and Progression

2.1. Metabolic Alterations

IDH mutations result in significant alterations and reprogramming of the cellular metabolic pathways. Indeed, the production of D2-HG leads to significant reduction and drainage of Krebs cycle substrates, and thus carbohydrate sources [24] [35]. Consequently, the Krebs cycle is forced to adjust and drain other carbohydrate sources to yield ATP [36–38].

Glutamine derivatives can serve as key substrates to the Krebs cycle compensating for the exhaustion of isocitrate by mutant IDH. Glutamate dehydrogenase 2, the enzyme responsible for the conversion of glutamate to α -KG has been found highly expressed in IDH mutant brain cells, to possibly compensate the reduction of α -KG consequent to IDH mutation [39]. In addition, IDH-mutated glioma cells are highly sensitive to the inhibition of glutaminase, an enzyme that contributes to the lysis of glutamate, further adding to the notion that IDH mutated cells are glutamate-dependent [40]. Additionally, the depletion of NADPH caused by the formation of D2-HG, leads to the reduction of intracellular lipogenesis, resulting in a great dependence in exogenous lipid sources [2] and as such, partly explaining the slow but steady growth of IDH mutant gliomas.

Compared to other tumours, IDH mutant gliomas show a distinctive metabolic behaviour. In the majority of cancers, the need for an adequate supply of energy is mediated by the increased expression of lactate dehydrogenase (LDH) [41]. LDH catalyses the transformation of pyruvate, the end product of glycolysis, to L-lactate [42]. L-lactate can serve as immediate fuel for the increased demands for energy, to match the rapid proliferative potential of the cancer cells. On the contrary, in IDH mutated glioma patient-derived samples, the LDH is silenced [43,44]. Hypermethylation of the promoter region of the LDH gene was found to be the main reason for the lack of LDH expression [43,44]. This epigenetic silencing might explain the slow-growing nature of IDH mutants compared to IDH wild-type gliomas [44,45].

Moreover, IDH mutant gliomas seem to rely less on the glycolytic pathway, and more on oxidative phosphorylation to produce energy compared to the WT IDH1 gliomas [46]. A reduction in the glycolytic pathway, might not only partially explains the slow-growing nature of IDH mutant gliomas, but provides useful metabolic targets for future IDH mutant glioma therapies.

2.2. Redox Imbalance

IDH mutations lead to the increased affinity for NADPH and α -KG, leading to the conclusion that the mutant glioma cells will prefer using NADPH and not NADP⁺ [24] [47]. The high consumption of NADPH disrupts the reducing equivalents of biochemical reactions leading to the accumulation of reactive oxygen species (ROS) [48] [49]. ROS are involved in genomic instability, cellular motility and acquisition of invasive characteristics [50]. Excessive ROS leads to DNA and protein damage, disrupting enzymatic reactions and gene expression. The alteration of gene expression might lead to new mutations, which are oncogenic. Consequently, the ROS accumulation is fundamental and a hallmark to cancer biology, especially for the IDH mutated gliomas. Cells derived from IDH1 mutated gliomas exhibit strong oxidative stress, evident by the increased expression of manganese superoxide dismutase [51]. The elevated stress was confirmed with further evaluation shown that IDH mutated cells are prone to oxidative damage [52] [53]. In the face of the raised oxidative profile enhancing antioxidant pathways, such as synthesis of glutathione, maybe be a valuable strategy to downplay the oncogenic effects of ROS [54].

2.3. Epigenetic Modifications

Epigenetic alterations are mechanisms that affect gene expression without causing permanent changes to the DNA sequence as mutations would. Epigenetic changes range from DNA methylation, non-coding RNA molecules and covalent modifications to histones, such as acetylation, methylation and phosphorylation [55] [56]. IDH mutations are very tightly linked with changes to the epigenetic landscape in cells and this is due to their abnormal production of D2-HG, which competitively

inhibits a range of enzymes involved in maintaining “normal” DNA methylation. The resulting disruption leads to genome wide changes in epigenetics called hypermethylation and leads to widespread alterations in gene expression [57]. Understanding the pathogenesis of IDH mutant gliomas in relation to the hypermethylation patterns might lead to the identification of rational therapeutic targets.

Analysis for DNA methylation changes of GBM samples data from *The Cancer Genome Atlas* (TCGA) database found a strict correlation between IDH mutation and the development of a unique DNA methylation signature [58,59]. This came to be known as the glioma cytosine-phosphate-guanine (CpG) island methylator phenotype (G-CIMP). The G-CIMP phenotype is considered a favourable marker of prognosis only in patients affected by IDH mutant gliomas [60], although an increased hypermethylation on CpG sites of the genome, has been partially found in other IDH mutant tumours compared to their wildtype counterparts [57]. A study by Unruh and colleagues demonstrated that the extent and targets of the DNA hypermethylation induced by mutant IDH is highly variable between various IDH mutant cancers (AML, cholangiocarcinomas, melanomas, gliomas), depending on the cellular contexts and this might explain why mutant IDH is a favorable prognostic marker specifically in gliomas and not in other IDH mutant tumours [57].

Methyltransferases and demethylases are able to control the DNA methylation pattern. Within the demethylation process, 5-methylcytosine is converted to 5-hydroxymethylcytosine (5-hmC) catalyzed by methylcytosine dioxygenase TET, in an α -KG and iron-dependent manner. In addition, TET concomitantly catalyses cytosine demethylation steps by converting 5-hmC to 5-carboxylcytosine (5-caC) and -formylcytosine. Thymine DNA glycosylase BER enzymes will eventually convert 5ca-C to cytosine [61]. However, in IDH mutant gliomas, the TET activity is inhibited due to D2-HG, which has a structural similarity to α -KG [34] [62]. Therefore, the DNA demethylation process cannot take place, and consequently an hypermethylated phenotype is present in mutant IDH gliomas [63] [64]. Follow up studies have shown that once the hypermethylation happens, it is irreversible and thus playing a pivotal role in malignant transformation and recurrence [65].

Furthermore, D2-HG is aiding histone methylation by inhibiting histone demethylases. A notable example will be lysine-specific demethylase KDM [34] [27]. Histone methylation is predominantly regulated via histone methyltransferases, which add the methyl group as well as demethylases (such as KDM), which remove the methyl group. Due to the fact that α -KG is playing a catalytic role in these reactions, in a similar way as with the aforementioned TET, the increased levels of D2-HG competitively block the reactions [38]. It is now recognised that histone and CpG island hypermethylation patterns are predominantly found in IDH mutant glioma stem cells (GSCs) [29]. Studies have shown that CpG hypermethylation leads to inactivation of tumour suppressor genes (TSG) as well as altered gene expression related to cell differentiation [66]. Thus, the IDH mutations ultimately block cell differentiation and cell cycle regulation, leading to uncontrolled proliferation, with concomitant accumulation of new somatic mutations, which are acquired across time and remain undetected. However, the development of glioma not only requires seeds (GSCs) with uncontrolled proliferation but also a fertile soil (tumour microenvironment).

2.4. Tumour Microenvironment

The D2-HG produced by mutant IDH accumulates at mM ranges both intracellularly [24] [25] and extracellularly [67], causing not only a biochemical cascade of events inside the cell, but also important metabolic alterations in the surrounding cellular microenvironment. These metabolic changes may affect the behavior of the non-neoplastic cells present in the tissue in a multitude of ways to ultimately promote tumor growth and progression through non-cell intrinsic mechanisms.

2.4.1. IDH mutation and tumour-specific immune cells

The microenvironment surrounding glioma is rife with a variety of immune cells including tumour infiltrating lymphocytes (TILs), natural killer (NK) cells, tumour associated macrophages (TAMs), microglia, myeloid-derived suppressor cells (MDSCs), neutrophils, dendritic cells, and fibroblasts [68].

Increasing evidence have indicated that mutant IDH is able to decrease the levels of tumour immune surveillance, enabling cells to escape it. Various gliomas studies have shown that mutant IDH affect tumour immune-cell infiltration and function by modulating chemokine secretion. For instance, IDH1 mutation has been shown to reduce leukocyte chemotaxis into gliomas in a syngenic mouse model, by repressing the expression of key chemoattractant cytokine genes including *Cxcl-2*, *Ccl-2* and *C5* [69]. Other studies demonstrated that IDH mutant human gliomas have reduced levels of CD8+T lymphocytes compared to their WT counterpart; this was also confirmed by using syngenic mouse model of glioma, where expression of mutant IDH or a treatment with 2-HG reduced infiltration of cytotoxic CD8+T lymphocytes and levels of T cells-associated chemokines within tumours. Interestingly, these effects were reversible by using a specific inhibitor of mutant IDH1 [70]. Accordingly, other studies reported that glioma stem cells and astrocytes expressing IDH-mutations are able to escape immune surveillance, by causing an epigenetic repression of natural killer cells ligand genes [71]. The inhibition of the immune response caused by mutant IDH might explain at least in part, the difference of aggressiveness of IDH-mutant gliomas compared to the wild type samples.

Many recent studies have also indicated that IDH mutation modifies TAM phenotypes to influence glioma growth. TAMs are the main innate immune effector cells in malignant gliomas and can be separated into two categories, M₁ with a pro-inflammatory signature and M₂ with an anti-inflammatory signature [72]. Mutant IDH has been found to reduce infiltration of TAMs in both IDH1-mutant mouse model and human glioma tissues [69]. Another study found that although the total number of TAMs is lower in IDH1-mutant compared to the WT IDH GBM samples, the remaining TAMs are more pro-inflammatory [73]. Conversely, another recent study reported that TAMs from patients with IDH-mutant gliomas exhibit a more immunosuppressive phenotype than IDH-wild-type samples [74].

Mutation in IDH1 plays an important role in TAM activation. D2-HG can be taken up by TAMs using membrane transporters and favors the activation of the M1 state of TAMs [75]. An *in vitro* assay combining human TAMs with glioma cells for 24 hours showed that the presence of IDH1 mutation within the glioma cells caused an increase in the expression of M1 genes and a decrease in that of the M2 genes [75]. Moreover, mutation in IDH1 also promotes TAM migration *in vitro* and *in vivo*; conditioned medium derived from IDH1-mutant glioma cells significantly promotes TAM migration compared with that from IDH1-wild-type glioma cells. Accordingly, *in vivo* data showed that the IDH1-mutant glioma cells have increased TAM recruitment, which promotes the anti-tumour functions of TAMs *in vivo* [75].

Migration of both CD4⁺ and CD8⁺ T cells is inhibited by application of D2-HG whilst T cell proliferation and production of IFN γ were both inhibited in a dose-dependent manner [76]. This provides direct evidence that D2-HG produced by mutant IDH has a vital role in immune suppression.

The role of D2-HG was further elucidated using genetically-engineered CAR-T cells. CAR-T cells were generated that were either a KO or OE of the D2-HGDH enzyme – D2-HG dehydrogenase – which takes D2-HG as its substrate and produces α -ketoglutarate. The KO and OE CAR-T cells were tested using the cell line NALM6 overexpressing mutant IDH1. The results show that D2-HGDH-OE CAR-T cells had a profound rate of tumour cell death compared to that of the D2-HGDH-KO CAR-T cells. Mice bearing mutant IDH1 tumours showed a significant increase in their survival following treatment with D2-HGDH-OE CAR-T cells. It was later shown that the mechanism behind this was down to the reduction in D2-HG, and therefore the removal of immune suppression, allowing for an increase in memory cell differentiation and cytokine production [77].

A recent study provides new evidence for mechanistic insight for the effects of D2-HG on CD8⁺ T-cell inhibition [78]. Notarangelo *et al* showed that D2-HG acts directly on CD8⁺ T-cells to impair cytokine production and proliferation in a reversible and dose-dependent manner leading to suppression of this immune cell group. The study went further to show that D2-HG inhibits the ability of CD8⁺ T-cells to perform glycolysis by direct inhibition of lactate dehydrogenase (LDH). *In vitro* studies using purified, recombinant LDH protein and exogenous D2-HG showed a non-competitive inhibition of the enzyme leading to altered glycolytic flux in the CD8⁺ T-cells. Application of D2-HG to CD8⁺ T-cells led to a reduction in the production of IFN- γ and therefore also in its autocrine effects

on gene expression. Encouragingly, the effects seen *in vitro* are also found *in vivo* when analysing samples from IDH-mutant tumours. These glioma samples demonstrate reduced IFN- γ related gene expression as well as reduced lactate levels due to the inhibition by D2-HG [78].

Together, this data shows that mutant IDH enzyme, via the aberrant production of D2-HG, leads to suppression of the immune system both in terms of activation and infiltration. Overall, this leads to an immunologically “cold” tumour microenvironment, which improves overall patient survival but does limit treatment options as immune targeted therapies are rendered ineffective. Further understanding the difference in the role of the immune system in both IDH WT and mutant gliomas will be essential to finding ways to effectively target these tumours.

2.4.2. IDH mutation, intra-tumour hypoxia and angiogenesis

Contrasting data exist in the literature regarding the ability of mutant IDH to increase the levels of hypoxia and the formation of new blood vessels in the tumour. It was originally hypothesized that 2-HG produced by mutant IDH, by competing with α -ketoglutarate may inhibit the prolyl hydroxylase (HIF-PHD) responsible for the ubiquitination and proteasomal degradation of hypoxia inducible factor (HIF), enabling HIF to become stable in normoxic conditions, and thus leading the expression of HIF-target genes, such as vascular endothelial growth factor (VEGF) [79] [27]. Accordingly, HIF1 α was found upregulated in cells overexpressing mutant *IDH1*, in cells treated with exogenous 2-HG and in IDH mutant tumors and in brains of mouse embryos expressing *idh1* R132H [79] [27] [80]. However, D2-HG has been found to be only a relatively weak inhibitor of HIF-PHD [27] and following studies found no correlation between IDH mutation status and the expression of HIF1 α in patients with glioma [81,82], or in brains of adult mice where mutant *idh1* has been expressed [83]. Additionally, other studies demonstrated that D2-HG can stimulate rather than inhibit the activity of HIF-PHD, and in some cellular contexts, such as human astrocyte, colorectal and erythroleukemia cell lines, the expression of IDH1 R132H reduced HIF levels [47,84]. Recently other studies found decreased levels of VEGF in IDH mutant compared to WT GBM samples and that the expression of HIF2 α and microvessel density were independent from IDH mutation status [85]. On the same line a gene set variation analysis of a cohort of TCGA patients has shown that IDH1/2 mutations were associated with an inhibition of angiogenesis signalling pathways. The same study found also that IDH mutant gliomas tend to have a lower relative cerebral blood volume compared to the IDH WT counterpart, indicative of a decreased angiogenesis of IDH mutant samples compared to the WT [86]. However, other findings reported that in primary GBM, intra-tumoral levels HIF1 α and peripheral serum levels of VEGF were significantly higher in IDH1 mutated versus IDH WT samples [87]. Thus, these discrepancies may be due to experiments being conducted in cells originating from different tissues and organs but might also arise from the subset of genetic changes characterizing the different type of tumours analysed. Consequently, a link between IDH mutation status and the hypoxia-induced angiogenesis is clearly not a straightforward phenomenon, and the difference in cellular contexts and in the associated genetic changes between different tumours may cause contrasting experimental results. However, albeit controversial, these findings are interesting as highlight the possibility that HIF, despite being traditionally viewed as an oncogene, it may also act as a tumor suppressor under certain condition.

2.4.3. IDH mutation and tumour-associated epilepsy

Patients affected by IDH mutant gliomas present a more frequent epileptic activity compared to IDH wildtype patients [88] [89]. Unfortunately, the seizures showed by IDH mutant patients are frequently resistant to first line epilepsy treatment [90]. Nevertheless, recently it has been reported that a patient affected by IDH1 mutant oligodendroglioma showed reduced tumor-associated epilepsy after treatment with the IDH1 mutant inhibitor AG-120 (ivosidenib) [91]. To explain the higher incidence of seizures in IDH mutant patients compared to the IDH wildtype patients, the neuroexcitatory properties of the D2-HG need to be considered. D2-HG is released by IDH mutant glioma cells into the tissue microenvironment, and it has structural similarities to glutamate, thus it may communicate to the surrounding neurons via the interaction with the NMDA receptor [92]. Indeed, it has been

demonstrated that activation of NMDA receptors, whether by glutamate or D2-HG, leads to an increase in membrane excitation and thus, epilepsy [93] [94]. The epileptogenic activity elicited by IDH mutation on the neighboring neurons has been recently demonstrated to be triggered by the mTOR pathway and it can be blocked by the addition of rapamycin [77]. However, the concentrations of extracellular D2-HG produced by mutant IDH can reach the mM range [95], whilst the normal extracellular concentration of glutamate is estimated to be between the nM and μ M range [96]. This suggests that levels of D2-HG in mutant IDH gliomas, by leading to an exacerbated or prolonged activation of glutamate receptors may also be excitotoxic.

2.5. The role of IDH mutation in tumour invasion

Glioma cell invasion is one of the main reasons for tumour recurrence and thus poor prognosis. The exact mechanisms underlying invasion are yet to be elucidated but mathematical modelling using data obtained from MRI scans has demonstrated that IDH mutant tumours are less aggressive but more diffuse and invasive than their WT counterparts [97]. To explain this phenomenon, it has been proposed that IDH mutant tumours are able to modulate their microenvironment, by increasing the extracellular levels of D2-HG. High levels of D2-HG might acidify the stroma of the tumour to a degree that is toxic to normal cells, causing the degeneration of the tissue and formation of space for migration of glioma cells [97]. However, since no evidence of extensive acidosis and tissue damage is observed in the majority of grade II and grade III gliomas, where normally D2-HG production occurs, alternative explanations have also emerged. It has been proposed that glioma cells, and especially IDH mutant cells, in which α KG and NADPH levels are decreased [98], import glutamate from the tumor microenvironment, which is used to produce α KG in the anaplerotic reaction glutaminolysis. Therefore, in IDH-mutated glioma cells the neurotransmitter glutamate could act as a chemotactic compound [99].

In colorectal cancer cells exogenous administration of D2-HG, was found to directly induce epithelial-mesenchymal transition (EMT) by increasing the genetic expression of ZEB1, a master regulator of EMT; consequently, D2-HG was found to promote cancer cells motility and invasion. Interestingly D2-HG was applied at 250 μ M whilst endogenous production by IDH mutation has been known to reach the mM range [95]. This would suggest that this phenomenon may be present even at an enhanced level in human disease. The same study found that elevated levels of D2-HG were present in some colorectal cancer cells and specimens in absence of mutations in IDH. In particular, colorectal cancers with high levels of D2-HG were the samples with an increased frequency of distant organ metastasis [100]. Another study involving glioma cell lines T98 and U87 also showed that exogenous application of D2-HG led to the increase in cell proliferation and invasion. This study went one step further by introducing the IDH1 R132H mutation via a lentiviral transduction method. These cells - along with non-transduced, D2-HG treated cells - had an increase in protein expression of β -catenin, which is involved in the invasion-associated epithelial-mesenchymal transition [101]. Interestingly, another study utilizing overexpression of IDH1 R132H in U87 and U251 cells demonstrated the opposite effect on cell proliferation and invasion whilst also having a negative effect on β -catenin [102]. This contradictory evidence suggests that IDH mutation, subsequent production of D2-HG and cell invasion mechanisms are not linear in nature and may have many other factors involved which can be influenced by experimental conditions.

Interestingly, *in vivo* studies in which IDH1 R132H was selectively induced in the brain subventricular zone (SVZ) of the adult mouse demonstrated that SVZ cells gained the ability to proliferate ectopically and spread outside of the SVZ into the surrounding brain regions, a process which in healthy mice does not occur [83]. This indicates that IDH1 mutation grants cells the capability of invasion into the nearby parenchyma in the early stages of tumour development.

2.6. The emerging role of IDH3 in cancer and beyond

IDH3 is the third member of the IDH family and a key enzyme of the TCA cycle. As mentioned previously, IDH3 catalyzes the irreversible conversion of isocitrate to α KG, meanwhile reducing

NAD⁺ to NADH [103]. NADH produced during the TCA cycle, is then used to generate ATP by the electron transport chain [104].

Increasing experimental evidence indicates that IDH3 is involved in the epigenetic regulation of the genome. The α KG is an obligatory cofactor of the α KG-dependent dioxygenases, a superfamily of enzymes involved in many biological processes including epigenetic regulation of gene transcription [105]. Consequently IDH3, by producing α KG, may modulate the enzymatic function the α KG-dependent dioxygenases, and consequently influence the demethylation of DNA and histones. It has been demonstrated that like several other TCA enzymes, such as pyruvate decarboxylase and pyruvate dehydrogenase, IDH3A localizes temporarily to the nucleus during the zygotic development, and it contributes to the expression of genes important for zygotic genome activation and developmental progression [106]. Another recent study demonstrated that mitochondrial metabolites, including TCA cycle intermediates, play critical roles in regulating cell pluripotency. During somatic cell reprogramming to pluripotency acquisition, many TCA cycle enzymes, including Idh3a localized to the nucleus to induce epigenetic remodeling [107]. Moreover recently, a nonclassical and incomplete TCA cycle was discovered in the nucleus of eukaryotic cells, to possibly generate and consume metabolic intermediates used not for energy production, but for epigenetic regulation [108].

Loss-of-function and missense mutations in both *IDH3A* and *IDH3B* have been linked to inherited retinal diseases (IRD's), which are a leading cause of blindness in children and adults [109] [110] [111]. Besides, like many other TCA cycles enzymes, whose genetic mutations have been implicated in neurological disorders [112–120], homozygous missense mutation (p.Pro304His) in *IDH3A* have been associated to a severe form of encephalopathy, which causes neurological defects from birth and retinal degeneration [121].

Currently *IDH3* has not been found to be mutated in any tumours. In a screen of 47 glioblastoma samples, no *IDH3* mutations were found [122]. However, abnormal expression of IDH3 has been implicated in the cause and development of several cancers [123–126].

IDH3 α has been found to be overexpressed in various human cancer cell lines [123] and cancers [126], and in patients affected by human hepatocellular carcinoma (HCC) [126], lung and breast cancers [123] high levels of IDH3 α expression were correlated with a poor prognosis. Interestingly, IDH3 α was identified as a novel upstream activator of HIF-1 α . *In vitro* data showed that IDH3 α overexpression results in an upregulation of HIF1 α in both normoxic and hypoxic conditions. By reducing the level of intracellular α -KG, aberrant expression of IDH3 α was found to suppress the hydroxylation of the HIF-1 α protein, and consequently to upregulate HIF-1 α stability and transactivating activity. Accordingly, *in vivo* data showed that overexpression of IDH3 α significantly accelerated the growth of HeLa/IDH3 α xenograft tumours, while silencing IDH3 α was observed to obstruct tumor growth [123]. IDH3 was found to be overexpressed also in GBM and it was found to promote GBM progression, through its essential role to the one-carbon metabolism, which regulates nucleotide production as well as DNA methylation through effect on cytosolic serine hydroxymethyltransferase (cSHMT) [124]. Interestingly, it was found that cells on the leading edge of the tumour expressed IDH3 α more than those in the centre of the tumour.

Recently, IDH3 α has been found to promote the progression of HCC by inducing expression of metastasis associated 1 (*MTA1*), an oncogene regulating cancer progression and metastasis [126]. Aberrant expression of IDH3 α in HCC cells has been found to promote epithelial-mesenchymal transition by inducing *MTA1* expression and thereby increasing cell migration and invasion [126].

In contrast, it was found that the downregulation of IDH3 α promotes the transformation of fibroblasts into cancer-associated fibroblasts by up-regulating HIF-1 α , which in turn caused a switch from oxidative phosphorylation to glycolysis [125].

All these studies demonstrated that although the role of IDH3 in cancer is still not clear, the impact of IDH3 on tumour initiation and progression is definitively context dependent; while in some cell types aberrant expression of IDH3 is advantageous, in others downmodulation of IDH3 is important to promote cell transformation. The various effects of IDH α on different cell types could be explained by the specific metabolic requirements of each different tissue during malignant transformation.

3. Novel Therapeutic Options for IDH Mutant Glioma

3.1. Direct Inhibition of mutant IDH

Over the last decade there has been a rapid development of direct inhibitors of mutant IDH, aimed to decrease the levels of D2-HG or 2-HG in IDH-mutant tumours. AGI-5198 has been reported as the first novel, synthetic, direct enzyme inhibitor of IDH [127]. Celgene Corporation and Agios Pharmaceuticals was the first collaboration to generate IDH mutant inhibitors via high-throughput screening campaign. AGI-5198 is a phenyl-arginine based compound able to block the generation of 2-HG produced by IDH mutant cells by 90%, and to impair the growth of IDH mutant xenograft *in vivo* [128]. As reported by Rohle and colleagues the AGI-5198 showed efficacy in patient-derived glioma xenograft models but the drug was also able to induce the differentiation of glioma cells, to reduced cell proliferation and histone methylation. However, it is worth noting that the global DNA methylation leading to the glioma CIMP phenotype was notably unchanged after the administration of the drug [127]. A study using IDH1 mutant knock-in human astrocyte models later suggested that the IDH1 inhibition has a small effective time frame because the IDH1 mutation is likely to change from a 'driver' to a 'passenger' mutation [129]. Despite the reduced proliferation and histone modification, 4 days after the oncogenic insult, the drug was found to be incapable of blocking or reversing the IDH1 mutation phenotypic changes. Further, work by Tateishi and colleagues showed that treating patient-derived IDH1^{R132H} glioma tumour-spheres with the S-enantiomer of the AGI-5198 do not block cell proliferation despite the decrease of 2-HG levels, and *in vivo* data using an orthotopic xenograft glioblastoma IDH mutant model, showed similar survival of mice treated with the AGI-5198 S-enantiomer compared to the mice treated with vehicle [130]. These mixed results in glioma models can be explained by the fact that IDH mutations are an early event in gliomagenesis and an oncogenic driver in LGGs, however during tumour evolution IDH mutant gliomas acquire a plethora of other subsequent mutations, which might render gliomas, and especially high-grade gliomas, almost ineffective to IDH mutant inhibitors. Another hypothesis is that there might be an epigenetic memory that is indelible by the IDH mutation enzymatic inhibition. Thus, a combinatorial approach to treatment may be needed. In addition, the fact that AGI-5198 is rapidly metabolised and cleared leads to the conclusion that it might be a poor candidate for the use of clinical trials [131].

AG-120 (ivosidenib), AG-881 (vorasidenib) and AG-221 (enasidenib) are the second generations selective, reversible drug inhibitors produced, which are approved by F.D.A. for the treatment of acute myeloid leukaemia [132,133]. AG-221 was the first selective IDH mutant inhibitor drug to be approved by F.D.A in 2017, **Table 1**. Initially, via high-throughput screening, a precursor of the drug was chosen, being the most prevalent form of IDH2 in AML, IDH2^{R140Q} [134] [135]. The precursor was able to bind to an allosteric site of IDH2 within the heterodimer interface of the enzyme, much like its predecessor AG-6780 [136]. However, it was shown via x-ray crystallography that the heterodimer interface binding forces IDH2^{R140Q} to adopt a non-catalytic open conformation leading to inhibition consistent with the functional changes described in IDH1^{R123H} inhibition [137]. Subsequent modifications optimised the potency, solubility, clearance and bioavailability of the drug leading to the development of AG-221 [134]. AG-221 showed time-dependent potency leading to the reduction of 2-HG in biochemical assays [134] [134] [138] with subsequent 2-HG depletion in transgenic IDH2^{R140Q} TF-1 erythroleukemia cells and in patient-derived primary AML cells in both IDH2^{R140Q} and IDH2^{R172K} [134]. *In vivo*, within 20 days the mouse models with patient derived IDH2^{R140Q} AML produced cells specific markers of differentiation such as CD11b, CD14 and 15 with reduction in the CD17 immature marker with increase in survival. Regarding the use of AG-221 no information yet exists regarding its penetrance through the BBB in addition to the fact that IDH2 mutation are less abundant in gliomas did not lead to many clinical studies for glial tumours. Currently, there is a single trial of dose escalation for gliomas (NCT02273739, **Table 1** and other IDH mutant tumours, which started in 2014). The drug showed inhibitory effects for these tumours. However, appropriate dosing was an issue.

Drug Name	Target	Mechanism of Action	Advantages	Disadvantages	Current Clinical Trial in Gliomas (s)	Sponsor (s)
AG 120 Ivosidenib (F.D.A. Approved)	IDH1 R132C, H, G, S, L	Reversible, allosteric competitive inhibitor	F.D.A. approved in 2018 for relapse/refractory acute myeloid leukaemia and 2019 for newly diagnosed. In 2021, F.D.A received application for the drug to be assessed for cholangiocarcinoma. Currently, under investigation in a number of clinical trials in haematological malignancies.	Unknown if it penetrates the BBB, 4.1% penetration in rat model.	NCT02073994: Phase 1, multicentre, single group assignment, open-label, dose escalation/safety and clinical activity trial of oral administration for solid tumour including gliomas. 170 patients to be recruited by 2022. NCT03343197: A phase 1, randomised, multicentre, controlled, open label, parallel assignment, perioperative study of AG120 and AG881 in patients with non-enhancing IDH1 mutant glioma both grade II and III. 45 patients estimated.	Agios/Celgene
AG 221 Enasidenib (F.D.A. Approved)	IDH2 R140Q, R172K	Allosteric, non-competitive inhibitor	F.D.A. approved in 2017 for relapse/refractory acute myeloid. Currently, under investigation in a number of clinical trials in haematological malignancies.	No information on penetration through the BBB. with 21 participants.	NCT02273739: A phase 1/2 multicentre, open-label dose escalation trial for solid tumours including gliomas. Trial completed	Agios/Celgene
AG 881	Pan Inhibitor IDH1&2	Allosteric non-competitive inhibitor	Penetration of the BBB in rat model. Pan inhibitor with advanced clinical trial design showing good tolerability and safety profile.		NCT02481154: Phase 1, multicentre, open label, single group assignment, dose escalation/safety and clinical activity trial of oral administration for gliomas with IDH1 or IDH2 mutation. The trial was completed in 2021. NCT04164901: phase 3 multicenter, randomized, double-blind, placebo-controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation. Approximately 366 participants are planned to be randomised 1:1 to receive orally administered Vorasidenib 50 mg QD or placebo. Press release published March 2023.	Agios/Celgene

AGI 5198	IDH1 R132 C,H	Reversible, allosteric competitive inhibitor to alpha-KG	Penetrance of BBB in mouse glioma xenografts.		Agios/Celgene
BAY 1436032	IDH1 R132 C,G,H,L,S	Allosteric non-competitive inhibitor	Penetrance (low): 0.06-0.38 brain to plasma ratio) of BBB in mouse model.	NCT02746081: A phase 1, open label, non-randomised, multi-centre, of tolerance and pharmacodynamic evaluation in solid tumour with IDH1 mutation. 81 patients. NCT02381886: A phase 1, single group assignment, open label for advanced malignancies that harbour IDH132H mutations. 166 patients. 75-750 mg twice daily. Complete remission (CR) or CR with incomplete count recovery occurred in 10/37 (27%) patients with AML and 1/ 4 patients with myelodysplastic syndrome. Adverse events (AEs) suspected to be related to study drug were reported in 53.7% of patients. Results published March 2023.	Bayer
IDH 305	IDH1 R132 C,H	Allosteric non-competitive inhibitor	Penetrance of BBB in murine models.		Novartis
AGI 6780	IDH2 R140Q	Allosteric non-competitive inhibitor	Unknown penetrance through the BBB.		Agios/Celgene
FT-2102	IDH1 R132 C	Competitive inhibitor	Unknown penetrance through the BBB.	NCT03684811: A phase 1b/2 non-randomised, parallel assignment, open label study for recurrent/progressed glioma plus other tumours that have IDH1 mutation. 200 patients estimated.	Forma Hannover Medical School (Germany)
MFK A	IDH1 R132 C, H	Unknown	Penetrance through BBB in mouse model shown with brain-to-plasma ratio >1.	Unknown penetrance through the BBB.	Merck

GSK 321	IDH1 R132C, H, G	Reversible, allosteric, non-competitive inhibitor	Unknown penetration through the BBB.		GSK
ML 309	IDH1 R132H	Reversible inhibitor	Unknown penetration through the BBB.		
Ds 1001b	IDH1 R132X	Direct inhibitor	Shown to penetrate the BBB both in humans and mouse xenograft models. Designed to penetrate the BBB.	NCT03030066: A phase 1 single group assignment open label study. 47 participants. Twice-daily oral administration resulted in antitumor activity in patients with recurrent/progressive IDH1-mutated glioma. Results published in February 2023.	Daichi Sankyo

AG-120 (Ivosidenib) was developed by the Celgene/Agios aiming to optimise the AGI-5198 for human therapeutic applications [139]. Broad structure activity profiling led to the replacement of the cyclohexyl moieties with the fluorinated cycloalkyl groups, preventing oxidation by the liver [131], plus the addition of the pyrimidine ring allowed for better potency leading to the drug called AG-14100. However, AG-14100 was a potent liver enzyme inducer. Subsequent modification led to AG-120 with good potency and clearance. AG-120 is a specific allosteric, reversible inhibitor of IDH1m, competing with the magnesium, an essential co-factor for the enzyme, preventing the formation of the catalytic site [140]. AG-120 was shown to inhibit a plethora of IDH^{R132H} mutants cell lines selectively [141]. A significant disadvantage is the low penetrance (4.1%) in mouse models with intact BBB, which may be increased with a disrupted BBB in glioma models [127]. More animal studies are needed to evaluate its penetrance. Regarding mouse models, a dose dependent 2-HG depletion has been observed, across cell types including an IDH1^{R132H} mutant glioma xenograft mouse model [142] [127] [143]. In addition, the same articles reported that AG-120 was able to modulate some oncogenic properties of cancer cells such as inducing differentiation in AML myeloblasts and inhibiting invasion and migration in chondrosarcoma cell lines [142] [143] [144]. Thereafter, the drug was F.D.A. approved for refractory/relapsed AML and currently under investigation in 2 clinical glioma trials evaluating the efficacy and safety profile, **Table 1**. In 2015, the phase 1 data on the safety of AG-120 in patients with advanced gliomas amongst other solid tumours showed that the drug is well-tolerated with a promising pharmacokinetic profile [145]. In the trial, AG-120 was initially administered in a dose-escalation manner over 28 days ranging from 100mg to 1200mg. The maximum dose resulting in greater D2-HG reduction was the 500mg. Therefore, the 500mg was chosen for the dose expansion phase of the trial for both enhancing and non-enhancing IDH mutate gliomas [146]. Latest trial data showed that AG-120 optimal dosing regime of 500mg once a day led to 98% reduction of the 2-HG in cholangiocarcinoma and chondrosarcoma patients [146]. However, the plasma 2-HG levels for glioma population, did not seem to be a robust pharmacokinetic marker. Therefore, a second multi-centre trial is underway on recurrent LGG non-enhancing gliomas with IDH mutation using an AG-120 and AG-881, with primary outcome to compare the D2-HG concentrations in surgically removed tumours, which were treated versus not treated with the drug inhibitors [147]. Clinical safety, dosage, tolerance and pharmacokinetics are also to be studied. This safety, feasibility trial will provide appropriate dosing of AG-120 for future randomised studies. It is worth noting that the new inhibitors exhibit a good CSF-plasma ratio [131]. On the contrary, the main issue with the most common chemotherapeutic agent for HGGs, the TMZ, was whether the amount of the drug reaching the tumour might not be enough to eliminate the remaining of the cells. It is worth noting that no serious adverse events have been reported to date with the use of AG-120.

AG-881 also named Vorasidenib is the only oral pan-inhibitor for both IDH1 and IDH2 mutations, developed by Celgene and Agios Pharmaceuticals [148] [149] [150]. AG-881 was shown to bind the allosteric pocket at the dimer interface, leading to steroid hindrance and subsequent conformational change to an open and inactive state [149]. AG-881 though achieved more efficient inhibition *in vitro* with shorter incubation periods to the IDH1^{R132H} mutation [149]. Experiments showed the inhibition of 2-HG formation following 1h incubation in genetically engineered patient-derived TS603 glioma cell lines expressing IDH1^{R132C,G,H,L,S} [151]. In TF-1 and U87 transfected IDH2^{R140Q} and IDH2^{R172K} cells 2-HG inhibition was also shown, as well as inducing differentiation [150]. AG-881 was shown to penetrate the BBB in healthy rodents maybe showing promise to be used in humans. Indeed, AG-881 is currently under a phase 1, open label dose-escalation and expansion trial for the safety and pharmacokinetic properties to be investigated in both IDH1 and IDH2 mutated gliomas [152] [152]. According to the data presented in 2021, the drug shows favourable pharmacokinetic profile with no severe adverse effects and increase in survival to 24months in 60% of the patients [153]. The median progression-free survival was 36.8 months [95% confidence interval (CI), 11.2–40.8] for patients with non-enhancing glioma and 3.6 months (95% CI, 1.8–6.5) for patients with enhancing glioma. Previously, a dose range of 25-300mg were tested in the dose escalation arm and 10 or 50mg in the dose expansion arm [152]. Doses >100mg lead to toxicity. The most advanced clinical trial design is a phase 3 multicenter, randomized, double-blind, placebo-controlled study of AG-881 in subjects with

residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation **Table 1** [154]. Approximately 366 participants are planned to be randomized 1:1 to receive orally administered AG-881 50 mg QD or placebo, **Table 1**. There is now (March 2023) a press release out awaiting official results to be published.

BAY-1436032 is a relatively new specific, non-competitive IDH1m inhibitor with adequate pre-clinical results in AML and glioma models (**Table 1**). This compound is an allosteric IDH1 enzyme inhibitor, which binds to the dimer interface of mutant IDH [155]. BAY-1436032 was selected across a selection over 3million compounds based on IDH enzymatic activity with IC50 ranging from 0.6 to 17.1 micrometers [155]. The drug showed equivocal inhibition to all IDH1^{R132} mutants in AML human-derived cell lines and genetically engineered lines of solid tumours with reduced proliferation and induction of differentiation. In astrocytoma xenograft IDH1^{R132H} mouse models the drug showed effective penetration through the BBB with prolonged survival. There are two ongoing trials for AML and for solid tumours reviewed here [156]. The glioma trial is an open-label, non-randomized, multicenter phase I study to determine the maximum tolerated or recommended phase II dose of oral mutant IDH1 Inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics and preliminary pharmacodynamic and anti-tumor activity in patients with IDH1^{R132X} mutant advanced solid tumors including gliomas [157], **Table 1**. In dose escalation, 29 subjects with various tumour types across doses in the dose escalation ranging from 150 to 1500mg demonstrated a 76% reduction in D2-HG levels. A dose of 1,500mg was chosen for the dose expansion phase. 35 glioma patients showed 11% objective response rate and 43% stability of the disease [157]. The full results are to be published. Another new inhibitor, the MKR-A was able to achieve a robust intracranial 2-HG inhibition in the orthotopic mouse brain tumor models generated using BT142 and GB10 glioma cells, in which IDH mutation has naturally occurred. However, even with near complete inhibition of intratumoral 2-HG production, not all IDH mutant glioma models responded to treatment, but only BT142 displayed significant tumor growth inhibition resulting in a measurable survival benefit. Pronounced differences in the gene expression patterns between BT142 and GB10 tumors were also observed following MKR-A treatment [158].

IDH-305 is an allosteric non-competitive inhibitor of IDH1^{R132C,H} developed by Novartis. IDH-305 stabilises the enzyme via an inactive conformational change [159] showing efficacy in reducing 2-HG levels with substantial blood brain barrier penetrance in murine models. A current phase 1, single group assignment, open label for advanced malignancies that harbour IDH^{R132H} mutations trial has just been published, NCT02381886, Table 1 [160]. 35/41 patients demonstrated target engagement with reduction in 2-HG concentration at all doses -75-750 mg twice daily. Complete remission (CR) or CR with incomplete count recovery occurred in 10/37 (27%) patients with AML and 1/ 4 patients with myelodysplastic syndrome. Adverse events (AEs) suspected to be related to study drug were reported in 53.7% of patients. There are a number of new IDH1 specific inhibitors such as the FT-2102 IDH^{R132C} competitive inhibitor, which is in clinical trial monotherapy, **Table 1**. The Ds 1001b direct IDH1^{R132X} inhibitor with evidence of penetrance through the BBB both in humans and xenograft mouse models is also highly promising with the phase 1 single group assignment trial showing tolerance at 1400mg with a progression to phase 2 trial, [161] **Table 1**. The phase 1 showed that twice-daily oral administration resulted in antitumor activity in patients with recurrent/progressive IDH1-mutated glioma. A phase II study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutant WHO grade 2 gliomas is ongoing to verify the efficacy of DS-1001 as a single agent (NCT04458272).

A number of other new inhibitors are noted in the table with some promising results in other malignancies such as the AML outlined in another comprehensive review [156]. Despite the positive results, the success of IDH-mutant inhibitors is found to have a plethora of limitations in IDH mutant gliomas. A study showed that despite the fact that AGI-5198 reduces neomorphic activity, it also does not alleviate the DNA and histone hypermethylation phenotype since histone methylation was found to be high [129]. Further, Sulkowski and colleagues demonstrated that AGI-5198 is preventing DNA damage in cancer cells, leading to the conclusion that this might allow for resistance to DNA damage agents like current chemo and radiotherapeutic options [162]. This has also been confirmed by

another study, suspected that IDH1 mutated cells under the action of AGI-5198 gain radioprotective abilities [163]. Currently, a number of other novel molecular inhibitors are tested. Those can be combined with IDH inhibitors to overcome possible drawbacks of each, through umbrella and platform trials ongoing such as the Tessa Jowell BRAIN MATRIX Platform (TJBM) [164].

3.2. IDH Vaccine

IDH mutations are an early event in gliomagenesis [165], and are present in recurrent gliomas [166] [167]. This makes mutant IDH an excellent target for potential immune therapies. Initial attempts to produce vaccines against mutant IDH were performed by Schumacher *et al* where they inoculated mice with a 20 amino acid peptide spanning part of the mutated catalytic pocket of the IDH enzyme. This resulted in mice mounting a robust immune response from CD4⁺ T-helper cells, which were specific to the IDH mutation. The growth of subcutaneous sarcomas carrying either IDH1 WT or IDH1^{R132H} were investigated following preventative vaccination. Tumours positive for IDH1^{R132H} grew more slowly than those expressing the WT protein, following vaccination with the mutant IDH peptide vaccine [168], showing the efficacy of the anti-tumour therapy. A direct follow up to this initial vaccine research was the NOA16 trial, a first-in-human, single-arm phase 1 trial in which newly diagnosed patients with grades III and IV IDH1^{R132H} astrocytomas were recruited [169]. The presence of IDH mutation confers survival advantage to patients diagnosed with grade III or IV gliomas and so acts as a unique target for immune therapy [170] [171]. The trial comprised 8 vaccinations in total and 90.6% of participants experienced non-severe adverse effects. A greater percentage of trial participants experienced pseudoprogression – a phenomenon by which a tumour appears to have increased in size when viewed via imaging tests, but where no such growth has actually occurred – compared to a molecularly matched control group which was indicative of an immune response induced by the IDH1^{R132H} vaccine. However, the authors do concede that pseudoprogression seen may have been a delayed response from previous rounds of radiotherapy as they excluded patients presenting with pseudoprogression from the trial [169].

In summary, research conducted so far indicates that mutant IDH is a potential target for immunotherapy. The phase 1 NOA16 trial shows that the vaccine is well tolerated and safe thus paving the way for phase 2 trials to assess the vaccine's effectiveness. Patients included in the NOA16 trial were diagnosed with either WHO grade III or IV astrocytomas, leaving the door open for IDH vaccination research in oligodendroglioma to understand if IDH vaccination can be of benefit to this group. The IDH^{R132H} vaccine has made promising steps towards becoming a novel therapeutic option for glioma, however other cancers regularly display mutations in either IDH1 or IDH2, thus opening the possibility of also being susceptible to targeted IDH mutant vaccination. Glioma most commonly contains the IDH^{R132H} point mutation [172], however this is not strictly conserved in other cancers which have been shown to express variants including IDH1^{R132C} and IDH1^{R132G} but also mutations in IDH2, commonly, IDH2^{R140Q} and IDH2^{R172K} [173]. This means there is a wide range of potential targets for IDH specific vaccination treatments across different cancers.

3.3. Modulating Epigenetic Alterations in IDH mutant gliomas

As previously mentioned, the IDH mutation leads to histone and DNA hypermethylation patterns [26,27,29,57–59,62–66,174].

The hypermethylation phenotype might lead to oncogenic activities in IDH mutant cells, thus intervening with the epigenetic changes has been postulated as a potential therapeutic option for IDH mutant gliomas. Flavahan and colleagues have demonstrated that glioma CpG island methylator phenotype (G-CIMP) is linked to hypermethylation at sites for cohesion and CCCTC-binding factor (CTCF), leading to the reduced affinity of this protein [175]. The CTCF reduced binding affinity allows for enhancer mediated expression of PDGFR-A. PDGFR-A is a known mitogen that has been linked to gliomagenesis [176]. By administering a demethylating agent, they showed that the CTCF binding is partially restored and the PDGFR-A expression is reduced. The notion that by inhibiting hypermethylation, might be beneficial has also been documented by another study. Decitabine, a DNA methyltransferase inhibitor was able to suppress the proliferation both *in vitro* and *in vivo*, of

IDH mutant glioma cells [177]. Concomitantly, with the usage of 5-azacytidine, an analogue that controls the DNA methyltransferase activity, has led to reduced proliferation of IDH-mutated xenograft glioma model [178]. However, epigenetic changes are only a piece of the puzzle. Combinatorial therapies might be needed to tackle the oncogenic potential induced by IDH mutations.

3.4. Inhibiting DNA Repair

The DNA is susceptible to a range of damaging agents both from within the body, such as replication errors and toxins, and from outside the body, such as UV and ionising radiation [179]. Because of this, we have evolved an impressive array of mechanisms to counteract this damage including homologous repair (HR) and non-homologous end joining (NHEJ) [180].

As already mentioned, the tumorigenic effects of D2-HG are proposed to derive from modulating α KG-dependent dioxygenases, many of which are involved in histone and DNA methylation, but also enzymes playing key roles in the DNA damage response, such as alkB homolog (ALKBH) enzyme [181,182]. Wang *et al.* found that glioma cells expressing mutant IDH have reduced repair kinetics, accumulated more DNA damages and were sensible to alkylating agents. The sensitization to alkylating agents could be reversed by the overexpression of ALKBH2 or ALKBH3. This data indicates that alkylating agents may represent a valuable therapeutic option for treating IDH-mutated cancer patients [181].

D2-HG is also able to compromise the HR of DNA damage response [162]. Sulkowsky *et al.* found that application of a 2-HG analogue – 2R-octyl- α -hydroxyglutarate – to IDH1 WT cells caused an increase in double-strand breaks, suggesting that D2-HG was able to inhibit the HR pathway [162]. Alongside HR there is another pathway of DNA repair which relies on the poly(ADP-ribose) polymerase (PARP) family of enzymes. PARP enzymes play a role in the repair of single-strand breaks where they perform base-excision and nucleotide-excision repair [183]. Interestingly, when the HR pathway is inhibited in mutant IDH1 cell lines due to the D2-HG accumulation, PARP enzymes become a point of failure in the system. Specifically inhibiting PARP in these IDH1 mutant cells leads to the selective death of mutant but not WT cells. Conversely, inhibiting the neomorphic activity of mutant IDH1 with specific small molecule inhibitors reversed the deficiency in HR, with the number of double strand breaks almost returning back to that seen in IDH1 WT cells. Interestingly, the PARP inhibitor sensitivity induced by mutant IDH1 is present and functional in both patient-derived AML cells and glioma cells [162]. Taken together, this data indicates that IDH1 mutant cells are sensitive to the activity of PARP inhibitors, and this has the potential to be exploited in IDH mutant malignancies. In another study, it was demonstrated that by depleting NAD⁺, which is needed for PARP during TMZ induced BER, using GMX1778 as well as inhibiting Nicotinamide phosphoribosyltransferase (NAMPT) using FK866, eliminates the remaining of PARP of repair activity [130] [184]. This induces a specific metabolic stress response to TMZ-induced DNA damage and improves the duration of therapy response. Additionally, there is a currently active phase II/III trial – NCT02152982 – investigating whether the combination of TMZ and PARP inhibitor veliparib are more effective at treating newly diagnosed glioblastoma compared to TMZ alone. Recruited patients are required to have MGMT promoter methylation as this indicates that tumours are sensitive to TMZ and that the added inhibition of PARP DNA repair would further exacerbate DNA damage leading to a higher rate of cell death [185]. At the time of writing, this trial reached its primary completion date on the 1st December 2021, with the estimated study completion date being the 15th December 2024 (<https://clinicaltrials.gov/ct2/show/study/NCT02152982>).

Another type of DNA repair comes in form of telomere lengthening, which is a mechanism employed by cancer cells to maintain their growth over time [186]. Lower grade astrocytomas as well as secondary glioblastomas frequently have a loss of TERT which would normally mean that cells wouldn't be able to maintain their telomeres length thus resulting in stunted cell growth. However, TERT loss is usually accompanied by loss of ATRX and IDH1 mutation which when combined in cells is associated with alternative lengthening of telomeres (ALT) [187]. ALT is a poorly understood mechanism related to homologous recombination that allows for tumour cells to continue growing whilst protecting their telomeres from replicative shortening [188]. In low grade gliomas it may be

possible for IDH inhibitors to ameliorate the ALT phenotype since the triad of loss of TERT, loss of ATRX and IDH mutation are required to produce the ALT phenotype [187]. However, given IDH mutation is such an early event in gliomagenesis it may not be clinically realistic to administer inhibitors in time to prevent tumour formation. In light of this, there have been studies into inhibitors of the ALT mechanism itself including an inhibitor of ATR kinase which leads to an increase in the fragility of telomeres [188]. In conclusion genomic instability and glioma metabolism is interrelated and thus offer a unique area to explore therapeutic strategies.

3.5. Inhibiting Metabolic Pathways

IDH mutant enzymes cause the accumulation of D2-HG and thus draining some of Krebs cycle intermediates. Therefore anaplerotic pathways are recruited to compensate for the loss of Krebs cycle metabolites, such as α -KG. Understanding and delineating the new metabolic alterations, will allow us to evaluate potential druggable targets as novel therapeutic options. In IDH mutated glioma, the *de novo* production of NAD is reduced due to epigenetic silencing of nicotinamide phosphoribosyltransferase (*NAPRT1*). NAD is an important co-factor, pertinent to electron transport and metabolism of redox reactions, as it can carry H^+ ions and is derived from *de novo* and salvage pathways [189]. In IDH mutant glioma cells the *de novo* production of NAD is reduced. Therefore the only option for these cells is to generate NAD through salvage pathways [189] [130]. Thus, blocking the salvage pathway, by inhibiting the enzyme Nicotinamide phosphoribosyltransferase (NAMPT) can inhibit NAD production [190]. Thus in IDH-mutant glioma cells, where the *de novo* production of NAD is reduced by the silencing of *NAPRT1* gene, the inhibition of NAMPT leads to the reduction of NAD⁺ salvage pathways (NAMPT), resulting in a lack of metabolic substrate. This leads to biochemical crisis activating the energy sensor AMPK initiating autophagy. In contrast, the IDH wildtype cells had an increased expression of *NAPRT1* and alternative metabolic pathway to maintain energy supply of NAD⁺. In summary the study concluded that IDH1 mutation can make cells NAD⁺ dependent, thus it is a rationale therapeutic target in metabolic pathways.

Moreover, in IDH mutant cells glutaminolysis has been shown to be the major pathway of metabolic compensation due to lack of isocitrate [39]. Thus, targeting glutamine/ate metabolism might deplete the energy sources and thus inhibit major anabolic functions of the IDH mutant cell. For instance, bis-2-[5-(9-phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl sulfide has been shown to block glutaminase and thus hampering the glutamate metabolism and reducing proliferation and growth in IDH mutant AML cell [40] [191]. Further, another drug called Zaprinast was able to block glutaminase and reduce the proliferation of IDH-mutated glioma cells [192]. Moreover, another glutamine inhibitor, a drug called telaglenastat (CB-839) was shown to cause reduced D2-HG production and to induce glioma differentiation [193]. A phase 1 RCT combining TMZ, radiotherapy and the glutaminase blocker CB-839, is about to start recruiting patients affected by IDH mutated diffuse and anaplastic astrocytomas [194]. By suppressing the glutaminolysis, tumour growth might cease, and differentiation might take place.

3.6. Modulating Redox Homeostasis

ROS are predominantly elevated in IDH mutated tumours [51] [195]. It was found that glutamine/ate and glutathione are reduced in IDH-mutated glioma cell compared to adjacent normal tissues. D2-HG is negatively correlated with the levels of glutathione. Therefore, glutathione may be essential for IDH mutant maintenance of redox homeostasis [196]. Increased consumption and thus, reduction of glutathione, suggests the increased burden of ROS scavenging. Understanding these relationships will allow for therapies able to intervene with redox homeostasis. Limiting the ROS scavenging, which is driven by glutathione, could be an add-on therapy to the existing or under trial therapies. As previously mentioned, CB-839 can lead to blockage of glutamine metabolism and thus impaired redox homeostasis as well as sensitisation to radiotherapy [197].

3.7. Differentiation therapy

One of the main consequences arising from IDH mutation, is its ability of blocking normal cellular differentiation. Studies performed in a variety of IDH mutant malignancies, have in fact demonstrated that mutant IDH can halt normal cell differentiation, causing an expansion of progenitor cells, which is thought to be an important steps in cancer development [29] [198] [199] [200] [80]. Inhibition of mutant IDH with small molecule inhibitors can release the differentiation block, and possibly hinder tumour growth.

In the glioma context, Rohle *et al.* demonstrated that inhibition of mutant IDH by using a small IDH mutant selective inhibitor, AGI-5198 hampered the *in vitro* and *in vivo* growth of an oligodendroglioma cell line (TS603) harboring an endogenous IDH1-R132H mutation. Treatment of mice xenografts with AGI-5198, caused an upregulation of many several genes involved in glial differentiation, while the *in vitro* treatment of TS603 cells with AGI-5198, showed a loss of repressive histone marks at the promoters of astrocytic marker genes. This study demonstrated that, at least in this model, targeting mutant IDH1 can impair glioma development *in vivo*, which is related to changes in cellular differentiation [127].

More recently, treatment of undifferentiated glioma cells, which ectopically express IDH mutation (BT142) with an IDH mutant inhibitor (MRK-A), has an undifferentiated cell state, showed *in vitro* a decrease expression of some key stem cell markers. Treatment of mice bearing orthotopic BT142 tumours with MRK-A showed a reduction in the 5mC DNA signature, indicating a release of the hypermethylation phenotype seen in IDH mutant tumours. Following treatment with MRK-A, showed a significant upregulation of 245 genes, which is in line with the removal of the hypermethylated phenotype. Mice that received MRK-A treatment show an extended survival and reduced Ki67 staining compared to their vehicle-treated control group [158]. This study has begun to explain how differentiation therapy may be of benefit in the treatment of IDH mutant brain tumours, as it removes the 2-HG-dependent hypermethylation phenotype and alters the expression of a wide range of genes, which may enable differentiation of the cells. Further work is needed to understand whether there are any long-term effects of releasing these genes from their suppression via methylation and also to understand if differentiation therapy can be combined with other treatment modalities.

The use of IDH inhibitors as differentiation therapy has been also shown in haematological malignancies such as acute myeloid leukaemia (AML). Wang *et al.* developed a specific inhibitor for the most commonly occurring IDH mutation in AML, IDH2-R140Q, AGI-6780. Treatment with this inhibitor of an erythroleukemia cell line which ectopically expressed IDH2-R140Q, decreased the levels of 2-HG and released these cells from the block to differentiation. Similar studies on IDH2-mutated primary human AML cells similarly demonstrated showed a reduction in 2-HG levels and an increased differentiation of mutated AML cells [136]. This data suggests that mutant IDH causes a block to differentiation that is released upon treatment with inhibitor.

More recent studies have shown that AG-120 (ivosidenib) treatment decreased intracellular levels of 2-hydroxyglutarate and induced differentiation in models of *IDH1*-mutated tumors [131] [201]. Recently, AG-120 has been licensed for use in relapsed or refractory AML [202]. AG-120 was tested in a phase I clinical trial where it was shown to induce a substantial remission in patients with mutant IDH relapsed-refractory AML [132].

Combination use of an IDH1 inhibitor, BAY1436032, and a DNA methyltransferase inhibitor, azacitidine, has proven to be a novel, clinically relevant drug combination in the treatment of AML. The frequency of leukaemia stem cells (LSCs) in PDX models was analysed and found that they were decreased 4.1-fold with azacytidine alone and 117-fold with BAY1436032 alone. However, the frequency of LSCs was reduced by 470-fold when the drugs were given sequentially and by 33,150-fold when given simultaneously. This data shows that it is important to continue evaluating the synergistic effects of different drugs. Similarly, azacitidine has also been shown to reverse the differentiation block caused by mutations in IDH2 in chondrosarcoma cell lines [203]. This raises the possibility that IDH mutant chondrosarcoma could be targeted by dual therapy in a similar way to AML outlined above.

Use of ivosidenib or enasidenib in the treatment of mutant IDH AML, presents a risk of the patient developing differentiation syndrome (DS) [204]. Whilst the exact cause of DS has yet to be established, it is currently thought to arise from the sudden release of cytokines from myeloid cells as they are forced to differentiate [205]. With this in mind, care must be taken when studying the effects of differentiation therapy in the treatment of brain tumours as there may be unintended consequences and symptoms for the patient.

4. Conclusion and Future Directions

IDH1 and IDH2 mutations are found in approximately 80% of World Health Organisation (WHO) grade II/III cases. We outline key metabolic alterations, , as well as epigenetic changes, redox imbalance, which might not be uniform across IDH mutant gliomas and ongoing targeted therapeutic options, with a number of clinical trials specific to IDH inhibition recently published. However, whether the metabolic effect holds a key role in oncogenesis and tumour progression or it is merely a consequence of initial gene mutations remains largely unclear. Here we outline pathways and treatments in support of a deranged metabolism driving disease process. New IDH1 mutant glioma models are needed to examine the spectrum of responses to treatment that may be observed clinically following the administration of IDH1 mutant inhibitors. Taking into consideration that current therapies fail to demonstrate improvement in glioma treatments, IDH induced biochemical alterations should be adequately understood and assessed as potential target.

Reference

1. Koh, H.J., et al., *Cytosolic NADP⁺-dependent isocitrate dehydrogenase plays a key role in lipid metabolism*. J Biol Chem, 2004. **279**(38): p. 39968-74.
2. Badur, M.G., et al., *Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells*. Cell Rep, 2018. **25**(6): p. 1680.
3. Lee, S.H., et al., *Role of NADP⁺-dependent isocitrate dehydrogenase (NADP⁺-ICDH) on cellular defence against oxidative injury by gamma-rays*. Int J Radiat Biol, 2004. **80**(9): p. 635-42.
4. Joseph, J.W., et al., *The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion*. J Biol Chem, 2006. **281**(47): p. 35624-32.
5. Leighton, F., et al., *The synthesis and turnover of rat liver peroxisomes. I. Fractionation of peroxisome proteins*. J Cell Biol, 1969. **41**(2): p. 521-35.
6. Yang, C., et al., *Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling*. Cancer Res, 2009. **69**(20): p. 7986-93.
7. Xu, X., et al., *Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity*. J Biol Chem, 2004. **279**(32): p. 33946-57.
8. Ma, T., et al., *The β and γ subunits play distinct functional roles in the $\alpha(2)\beta\gamma$ heterotetramer of human NAD-dependent isocitrate dehydrogenase*. Sci Rep, 2017. **7**: p. 41882.
9. Hurley, J.H., et al., *Catalytic mechanism of NADP⁺-dependent isocitrate dehydrogenase: implications from the structures of magnesium-isocitrate and NADP⁺ complexes*. Biochemistry, 1991. **30**(35): p. 8671-8.
10. Gabriel, J.L., P.R. Zervos, and G.W. Plaut, *Activity of purified NAD-specific isocitrate dehydrogenase at modulator and substrate concentrations approximating conditions in mitochondria*. Metabolism, 1986. **35**(7): p. 661-7.
11. Yan, H., et al., *IDH1 and IDH2 mutations in gliomas*. N Engl J Med, 2009. **360**(8): p. 765-73.
12. Parsons, D.W., et al., *An integrated genomic analysis of human glioblastoma multiforme*. Science, 2008. **321**(5897): p. 1807-12.
13. Hartmann, C., et al., *Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas*. Acta Neuropathologica, 2009. **118**(4): p. 469-474.
14. Balss, J., et al., *Analysis of the IDH1 codon 132 mutation in brain tumors*. Acta Neuropathologica, 2008. **116**(6): p. 597-602.
15. Ichimura, K., et al., *IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas*. Neuro-Oncology, 2009. **11**(4): p. 341-347.
16. Watanabe, T., et al., *IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas*. Am J Pathol, 2009. **174**(4): p. 1149-53.
17. Amary, M.F., et al., *IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours*. J Pathol, 2011. **224**(3): p. 334-43.
18. Borger, D.R., et al., *Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping*. Oncologist, 2012. **17**(1): p. 72-9.

19. Paschka, P., et al., *IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication*. J Clin Oncol, 2010. **28**(22): p. 3636-43.
20. Al-Khallaf, H., *Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight*. Cell Biosci, 2017. **7**: p. 37.
21. Ward, P.S., et al., *The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate*. Cancer Cell, 2010. **17**(3): p. 225-34.
22. Ward, P.S., et al., *Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production*. Oncogene, 2012. **31**(19): p. 2491-8.
23. Dang, L., et al., *Cancer-associated IDH1 mutations produce 2-hydroxyglutarate*. Nature, 2010. **465**(7300): p. 966.
24. Dang, L., et al., *Cancer-associated IDH1 mutations produce 2-hydroxyglutarate*. Nature, 2009. **462**(7274): p. 739-44.
25. Pope, W.B., et al., *Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy*. J Neurooncol, 2012. **107**(1): p. 197-205.
26. Xu, W., et al., *Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases*. Cancer Cell, 2011. **19**(1): p. 17-30.
27. Chowdhury, R., et al., *The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases*. EMBO Rep, 2011. **12**(5): p. 463-9.
28. Abbas, S., et al., *Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value*. Blood, 2010. **116**(12): p. 2122-6.
29. Figueroa, M.E., et al., *Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation*. Cancer Cell, 2010. **18**(6): p. 553-67.
30. Wang, H.Y., et al., *The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas*. J Exp Clin Cancer Res, 2016. **35**: p. 86.
31. Tesileanu, C.M.S., et al., *Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations*. Acta Neuropathol, 2021. **141**(6): p. 945-957.
32. Pusch, S., et al., *D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma*. Acta Neuropathol Commun, 2014. **2**: p. 19.
33. Avellaneda Matteo, D., et al., *Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency*. J Biol Chem, 2017. **292**(19): p. 7971-7983.
34. Xu, W., et al., *Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases*. Cancer Cell, 2011. **19**(1): p. 17-30.
35. Reitman, Z.J., et al., *Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome*. Proc Natl Acad Sci U S A, 2011. **108**(8): p. 3270-5.
36. Borodovsky, A., M.J. Seltzer, and G.J. Riggins, *Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2*. Curr Opin Oncol, 2012. **24**(1): p. 83-9.
37. Ohka, F., et al., *Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation*. Tumour Biol, 2014. **35**(6): p. 5911-20.
38. Maus, A. and G.J. Peters, *Glutamate and α -ketoglutarate: key players in glioma metabolism*. Amino Acids, 2017. **49**(1): p. 21-32.
39. Waitkus, M.S., et al., *Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1(R132H)-Induced Metabolic Liabilities*. Cancer Res, 2018. **78**(1): p. 36-50.
40. Seltzer, M.J., et al., *Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1*. Cancer Res, 2010. **70**(22): p. 8981-7.
41. Doherty, J.R. and J.L. Cleveland, *Targeting lactate metabolism for cancer therapeutics*. J Clin Invest, 2013. **123**(9): p. 3685-92.
42. Le, A., et al., *Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression*. Proc Natl Acad Sci U S A, 2010. **107**(5): p. 2037-42.
43. Khurshed, M., et al., *In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma*. Oncotarget, 2017. **8**(30): p. 49165-49177.
44. Chesnelong, C., et al., *Lactate dehydrogenase A silencing in IDH mutant gliomas*. Neuro Oncol, 2014. **16**(5): p. 686-95.
45. Chaumeil, M.M., et al., *Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring*. Neuroimage Clin, 2016. **12**: p. 180-9.
46. Hvinden, I.C., et al., *Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations*. Cell Reports Medicine, 2021. **2**(12): p. 100469.
47. Losman, J.A. and W.G. Kaelin, Jr., *What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer*. Genes Dev, 2013. **27**(8): p. 836-52.

48. Itsumi, M., et al., *Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio*. Cell Death Differ, 2015. **22**(11): p. 1837-45.
49. Liu, Y., et al., *Targeting IDH1-Mutated Malignancies with NRF2 Blockade*. J Natl Cancer Inst, 2019. **111**(10): p. 1033-1041.
50. Behrend, L., G. Henderson, and R.M. Zwacka, *Reactive oxygen species in oncogenic transformation*. Biochem Soc Trans, 2003. **31**(Pt 6): p. 1441-4.
51. Gilbert, M.R., et al., *Autophagy and oxidative stress in gliomas with IDH1 mutations*. Acta Neuropathol, 2014. **127**(2): p. 221-33.
52. Shi, J., et al., *Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation*. Tumour Biol, 2015. **36**(2): p. 655-62.
53. Mohrenz, I.V., et al., *Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death*. Apoptosis, 2013. **18**(11): p. 1416-1425.
54. Cai, S.J., et al., *Brusatol, an NRF2 inhibitor for future cancer therapeutic*. Cell Biosci, 2019. **9**: p. 45.
55. Grønbaek, K., C. Hother, and P.A. Jones, *Epigenetic changes in cancer*. Apmis, 2007. **115**(10): p. 1039-59.
56. Kimura, H., *Histone modifications for human epigenome analysis*. J Hum Genet, 2013. **58**(7): p. 439-45.
57. Unruh, D., et al., *Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers*. Sci Rep, 2019. **9**(1): p. 8946.
58. Noushmehr, H., et al., *Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma*. Cancer Cell, 2010. **17**(5): p. 510-22.
59. Christensen, B.C., et al., *DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma*. J Natl Cancer Inst, 2011. **103**(2): p. 143-53.
60. Malta, T.M., et al., *Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications*. Neuro Oncol, 2018. **20**(5): p. 608-620.
61. Tsukada, Y.-i., et al., *Histone demethylation by a family of JmjC domain-containing proteins*. Nature, 2006. **439**(7078): p. 811-816.
62. Kohli, R.M. and Y. Zhang, *TET enzymes, TDG and the dynamics of DNA demethylation*. Nature, 2013. **502**(7472): p. 472-9.
63. Carrillo, J.A., et al., *Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma*. AJNR Am J Neuroradiol, 2012. **33**(7): p. 1349-55.
64. Duncan, C.G., et al., *A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation*. Genome Res, 2012. **22**(12): p. 2339-55.
65. Turcan, S., et al., *Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence*. Nat Genet, 2018. **50**(1): p. 62-72.
66. Doi, A., et al., *Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts*. Nat Genet, 2009. **41**(12): p. 1350-3.
67. Linninger, A., et al., *Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system*. Neuro Oncol, 2018. **20**(9): p. 1197-1206.
68. Kalluri, A.L., P.P. Shah, and M. Lim, *The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches*. Int J Mol Sci, 2023. **24**(3).
69. Amankulor, N.M., et al., *Mutant IDH1 regulates the tumor-associated immune system in gliomas*. Genes Dev, 2017. **31**(8): p. 774-786.
70. Kohanbash, G., et al., *Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas*. J Clin Invest, 2017. **127**(4): p. 1425-1437.
71. Zhang, X., et al., *IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression*. Neuro Oncol, 2016. **18**(10): p. 1402-12.
72. Tang, F., et al., *Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma*. Neuroscience Bulletin, 2022. **38**(9): p. 1069-1084.
73. Poon, C.C., et al., *Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma*. Oncotarget, 2019. **10**(33): p. 3129-3143.
74. Friedrich, M., et al., *Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas*. Nat Cancer, 2021. **2**(7): p. 723-740.
75. Ma, D., et al., *Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1*. Cancer Lett, 2021. **517**: p. 35-45.
76. Zhang, L., et al., *D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells*. Clin Cancer Res, 2018. **24**(21): p. 5381-5391.
77. Mortazavi, A., et al., *IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation*. Neuro Oncol, 2022. **24**(9): p. 1423-1435.
78. Notarangelo, G., et al., *Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function*. Science, 2022. **377**(6614): p. 1519-1529.
79. Zhao, S., et al., *Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha*. Science, 2009. **324**(5924): p. 261-5.

80. Hirata, M., et al., *Mutant IDH is sufficient to initiate enchondromatosis in mice*. Proc Natl Acad Sci U S A, 2015. **112**(9): p. 2829-34.
81. Metellus, P., et al., *IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients*. J Neurooncol, 2011. **105**(3): p. 591-600.
82. Williams, S.C., et al., *R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 α upregulation in adult glioma*. Acta Neuropathol, 2011. **121**(2): p. 279-81.
83. Bardella, C., et al., *Expression of Idh1(R132H) in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis*. Cancer Cell, 2016. **30**(4): p. 578-594.
84. Koivunen, P., et al., *Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation*. Nature, 2012. **483**(7390): p. 484-8.
85. Polivka, J., Jr., et al., *IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme*. Oncotarget, 2018. **9**(23): p. 16462-16476.
86. Kickingeder, P., et al., *IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma*. Sci Rep, 2015. **5**: p. 16238.
87. Yalaza, C., et al., *R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme*. Ann Clin Lab Sci, 2017. **47**(3): p. 362-364.
88. Liubinas, S.V., et al., *IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas*. Epilepsia, 2014. **55**(9): p. 1438-43.
89. Chen, H., et al., *Mutant IDH1 and seizures in patients with glioma*. Neurology, 2017. **88**(19): p. 1805-1813.
90. Correia, C.E., et al., *Pharmacoresistant seizures and IDH mutation in low-grade gliomas*. Neurooncol Adv, 2021. **3**(1): p. vda146.
91. Chen, X., et al., *Structures of a constitutively active mutant of human IDH3 reveal new insights into the mechanisms of allosteric activation and the catalytic reaction*. J Biol Chem, 2022. **298**(12): p. 102695.
92. Kölker, S., et al., *NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria*. Eur J Neurosci, 2002. **16**(1): p. 21-8.
93. Armstrong, T.S., et al., *Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy*. Neuro Oncol, 2016. **18**(6): p. 779-89.
94. Lange, F., J. Hörschemeyer, and T. Kirschstein, *Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy*. Cells, 2021. **10**(5).
95. Andronesi, O.C., et al., *Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy*. Sci Transl Med, 2012. **4**(116): p. 116ra4.
96. Herman, M.A., B. Nahir, and C.E. Jahr, *Distribution of extracellular glutamate in the neuropil of hippocampus*. PLoS One, 2011. **6**(11): p. e26501.
97. Baldock, A.L., et al., *Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status*. Neuro Oncol, 2014. **16**(6): p. 779-86.
98. Molenaar, R.J., et al., *The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation*. Biochim Biophys Acta, 2014. **1846**(2): p. 326-41.
99. van Lith, S.A., et al., *Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas*. Neuro Oncol, 2014. **16**(12): p. 1669-70.
100. Colvin, H., et al., *Oncometabolite D-2-Hydroxyglutarate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer*. Sci Rep, 2016. **6**: p. 36289.
101. Lu, J., et al., *IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction*. J buon, 2019. **24**(6): p. 2458-2464.
102. Cui, D., et al., *R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/ β -catenin signaling*. Int J Biochem Cell Biol, 2016. **73**: p. 72-81.
103. Ramachandran, N. and R.F. Colman, *Chemical characterization of distinct subunits of pig heart DPN-specific isocitrate dehydrogenase*. J Biol Chem, 1980. **255**(18): p. 8859-64.
104. Barnes, L.D., G.D. Kuehn, and D.E. Atkinson, *Yeast diphosphopyridine nucleotide specific isocitrate dehydrogenase. Purification and some properties*. Biochemistry, 1971. **10**(21): p. 3939-44.
105. McDonough, M.A., et al., *Structural studies on human 2-oxoglutarate dependent oxygenases*. Curr Opin Struct Biol, 2010. **20**(6): p. 659-72.
106. Nagaraj, R., et al., *Nuclear Localization of Mitochondrial TCA Cycle Enzymes as a Critical Step in Mammalian Zygotic Genome Activation*. Cell, 2017. **168**(1-2): p. 210-223.e11.
107. Li, W., et al., *Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation*. Nat Commun, 2022. **13**(1): p. 7414.
108. Liu, X., et al., *The existence of a nonclassical TCA cycle in the nucleus that wires the metabolic-epigenetic circuitry*. Signal Transduct Target Ther, 2021. **6**(1): p. 375.
109. Hartong, D.T., et al., *Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle*. Nat Genet, 2008. **40**(10): p. 1230-4.

110. Pierrache, L.H.M., et al., *Whole-Exome Sequencing Identifies Biallelic IDH3A Variants as a Cause of Retinitis Pigmentosa Accompanied by Pseudocoloboma*. *Ophthalmology*, 2017. **124**(7): p. 992-1003.
111. Peter, V.G., et al., *A novel missense variant in IDH3A causes autosomal recessive retinitis pigmentosa*. *Ophthalmic Genet*, 2019. **40**(2): p. 177-181.
112. Spiegel, R., et al., *Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2*. *Am J Hum Genet*, 2012. **90**(3): p. 518-23.
113. Aptowitz, I., et al., *Liver disease in the Ashkenazi-Jewish lipoamide dehydrogenase deficiency*. *J Pediatr Gastroenterol Nutr*, 1997. **24**(5): p. 599-601.
114. Elpeleg, O.N., et al., *Lipoamide dehydrogenase deficiency: a new cause for recurrent myoglobinuria*. *Muscle Nerve*, 1997. **20**(2): p. 238-40.
115. Shany, E., et al., *Lipoamide dehydrogenase deficiency due to a novel mutation in the interface domain*. *Biochem Biophys Res Commun*, 1999. **262**(1): p. 163-6.
116. Rosenberg, M.J., et al., *Mutant deoxynucleotide carrier is associated with congenital microcephaly*. *Nat Genet*, 2002. **32**(1): p. 175-9.
117. Spiegel, R., et al., *SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis*. *Ann Neurol*, 2009. **66**(3): p. 419-24.
118. Alston, C.L., et al., *Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency*. *J Med Genet*, 2012. **49**(9): p. 569-77.
119. Jackson, C.B., et al., *Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency*. *J Med Genet*, 2014. **51**(3): p. 170-5.
120. Geller, C., et al., *Fumarate deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes*. *Neurology*, 1990. **40**(3 Pt 1): p. 495-9.
121. Fattal-Valevski, A., et al., *Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy*. *Neurogenetics*, 2017. **18**(1): p. 57-61.
122. Krell, D., et al., *Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma*. *PLoS One*, 2011. **6**(5): p. e19868.
123. Zeng, L., et al., *Aberrant IDH3 α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis*. *Oncogene*, 2015. **34**(36): p. 4758-66.
124. May, J.L., et al., *IDH3 α regulates one-carbon metabolism in glioblastoma*. *Sci Adv*, 2019. **5**(1): p. eaat0456.
125. Zhang, D., et al., *Metabolic reprogramming of cancer-associated fibroblasts by IDH3 α downregulation*. *Cell Rep*, 2015. **10**(8): p. 1335-48.
126. Liu, X., et al., *Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex*. *Am J Cancer Res*, 2020. **10**(10): p. 3212-3229.
127. Rohle, D., et al., *An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells*. *Science*, 2013. **340**(6132): p. 626-30.
128. Popovici-Muller, J., et al., *Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo*. *ACS Med Chem Lett*, 2012. **3**(10): p. 850-5.
129. Johannessen, T.A., et al., *Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis*. *Mol Cancer Res*, 2016. **14**(10): p. 976-983.
130. Tateishi, K., et al., *Extreme Vulnerability of IDH1 Mutant Cancers to NAD⁺ Depletion*. *Cancer Cell*, 2015. **28**(6): p. 773-784.
131. Popovici-Muller, J., et al., *Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers*. *ACS Med Chem Lett*, 2018. **9**(4): p. 300-305.
132. DiNardo, C.D., et al., *Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML*. *N Engl J Med*, 2018. **378**(25): p. 2386-2398.
133. Mellingshoff, I.K., et al., *Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma*. *Journal of Clinical Oncology*, 2018. **36**(15_suppl): p. 2002-2002.
134. Yen, K., et al., *AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations*. *Cancer Discov*, 2017. **7**(5): p. 478-493.
135. Marcucci, G., et al., *IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study*. *J Clin Oncol*, 2010. **28**(14): p. 2348-55.
136. Wang, F., et al., *Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation*. *Science*, 2013. **340**(6132): p. 622-6.
137. Yang, B., et al., *Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H*. *Cell Res*, 2010. **20**(11): p. 1188-200.
138. Stein, E.M., *Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia*. *Future Oncol*, 2018. **14**(1): p. 23-40.
139. Dhillon, S., *Ivosidenib: First Global Approval*. *Drugs*, 2018. **78**(14): p. 1509-1516.
140. Deng, G., et al., *Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule*. *J Biol Chem*, 2015. **290**(2): p. 762-74.

141. Bello, L., et al., *Angiogenesis and invasion in gliomas*. Cancer Treat Res, 2004. **117**: p. 263-84.
142. Heredia, V., et al., AG-120, a novel IDH1 targeted molecule, inhibits invasion and migration of chondrosarcoma cells *in vitro*. Annals of Oncology, 2017. **28**: p. v538.
143. Nicolay, B., et al., EXTH-59. THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL *IN VIVO*. Neuro-Oncology, 2017. **19**(suppl_6): p. vi86-vi86.
144. Yen, K., et al., Abstract 4956: Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model. Cancer Research, 2018. **78**(13_Supplement): p. 4956-4956.
145. Burris, H., et al., Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas. Molecular Cancer Therapeutics, 2015. **14**(12_Supplement_2): p. PL04-05-PL04-05.
146. Fan, B., et al., Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs, 2020. **38**(2): p. 433-444.
147. Mellinghoff, I.K., et al., PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1. Neuro Oncol., 2019. **21**(Suppl 3): p. iii2. doi: 10.1093/neuonc/noz126.004. Epub 2019 Sep 6.
148. Chen, J., J. Yang, and P. Cao, The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors. Mini Rev Med Chem, 2016. **16**(16): p. 1344-1358.
149. Ma, R. and C.H. Yun, Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochem Biophys Res Commun, 2018. **503**(4): p. 2912-2917.
150. Yen, K., et al., Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies. Molecular Cancer Therapeutics, 2018. **17**(1_Supplement): p. B126-B126.
151. Konteatis, Z., et al., Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett, 2020. **11**(2): p. 101-107.
152. Mellinghoff, I., et al., Actr-31. Phase 1 Study of Ag-881, an Inhibitor of Mutant Idh1 and Idh2: Results from the Recurrent/Progressive Glioma Population. Neuro Oncol., 2018. **20**(Suppl 6): p. vi18. doi: 10.1093/neuonc/noy148.064. Epub 2018 Nov 5.
153. Mellinghoff, I.K., et al., Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res, 2021. **27**(16): p. 4491-4499.
154. Mellinghoff, I.K., et al., INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. Journal of Clinical Oncology, 2020. **38**(15_suppl): p. TPS2574-TPS2574.
155. Pusch, S., et al., Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma *in vivo*. Acta Neuropathol, 2017. **133**(4): p. 629-644.
156. Golub, D., et al., Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Front Oncol, 2019. **9**: p. 417.
157. Heuser, M., et al., Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020. **34**(11): p. 2903-2913.
158. Kopinja, J., et al., A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit. Sci Rep, 2017. **7**(1): p. 13853.
159. Cho, Y.S., et al., Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett, 2017. **8**(10): p. 1116-1121.
160. DiNardo, C.D., et al., A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol, 2023. **149**(3): p. 1145-1158.
161. Natsume, A., et al., The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol, 2023. **25**(2): p. 326-336.
162. Sulkowski, P.L., et al., 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med, 2017. **9**(375).
163. Molenaar, R.J., et al., Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res, 2015. **75**(22): p. 4790-802.
164. Watts, C., et al., Protocol for the Tessa Jowell BRAIN MATRIX Platform Study. BMJ Open, 2022. **12**(9): p. e067123.
165. Lai, A., et al., Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol, 2011. **29**(34): p. 4482-90.
166. Johnson, B.E., et al., Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science, 2014. **343**(6167): p. 189-193.
167. Bai, H., et al., Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet, 2016. **48**(1): p. 59-66.
168. Schumacher, T., et al., A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014. **512**(7514): p. 324-7.

169. Platten, M., et al., *A vaccine targeting mutant IDH1 in newly diagnosed glioma*. *Nature*, 2021. **592**(7854): p. 463-468.
170. Wahner, H.C.W., et al., *Predicting survival in anaplastic astrocytoma patients in a single-center cohort of 108 patients*. *Radiat Oncol*, 2020. **15**(1): p. 282.
171. Christians, A., et al., *The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas*. *Acta Neuropathol Commun*, 2019. **7**(1): p. 156.
172. Huang, J., et al., *Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development*. *Front Oncol*, 2019. **9**: p. 506.
173. Waitkus, M.S., B.H. Diplas, and H. Yan, *Biological Role and Therapeutic Potential of IDH Mutations in Cancer*. *Cancer Cell*, 2018. **34**(2): p. 186-195.
174. Tsukada, Y., et al., *Histone demethylation by a family of JmjC domain-containing proteins*. *Nature*, 2006. **439**(7078): p. 811-6.
175. Flavahan, W.A., et al., *Insulator dysfunction and oncogene activation in IDH mutant gliomas*. *Nature*, 2016. **529**(7584): p. 110-114.
176. Lokker, N.A., et al., *Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors*. *Cancer Res*, 2002. **62**(13): p. 3729-35.
177. Turcan, S., et al., *Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine*. *Oncotarget*, 2013. **4**(10): p. 1729-36.
178. Borodovsky, A., et al., *5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft*. *Oncotarget*, 2013. **4**(10): p. 1737-47.
179. Rastogi, R.P., et al., *Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair*. *J Nucleic Acids*, 2010. **2010**: p. 592980.
180. Chatterjee, N. and G.C. Walker, *Mechanisms of DNA damage, repair, and mutagenesis*. *Environ Mol Mutagen*, 2017. **58**(5): p. 235-263.
181. Wang, P., et al., *Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents*. *Cell Rep*, 2015. **13**(11): p. 2353-2361.
182. Chen, F., et al., *Oncometabolites d- and l-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions*. *Chem Res Toxicol*, 2017. **30**(4): p. 1102-1110.
183. Morales, J., et al., *Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases*. *Crit Rev Eukaryot Gene Expr*, 2014. **24**(1): p. 15-28.
184. Tateishi, K., et al., *The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD(+) Depletion-Mediated Cytotoxicity*. *Cancer Res*, 2017. **77**(15): p. 4102-4115.
185. Gupta, S.K., et al., *Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma*. *J Natl Cancer Inst*, 2016. **108**(5).
186. Okamoto, K. and H. Seimiya, *Revisiting Telomere Shortening in Cancer*. *Cells*, 2019. **8**(2).
187. Mukherjee, J., et al., *Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma*. *Cancer Res*, 2018. **78**(11): p. 2966-2977.
188. Zhang, J.M. and L. Zou, *Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks*. *Cell Biosci*, 2020. **10**: p. 30.
189. Garten, A., et al., *Physiological and pathophysiological roles of NAMPT and NAD metabolism*. *Nat Rev Endocrinol*, 2015. **11**(9): p. 535-46.
190. Madala, H.R., et al., *Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies*. *Cancers (Basel)*, 2018. **10**(2).
191. Emadi, A., et al., *Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations*. *Exp Hematol*, 2014. **42**(4): p. 247-51.
192. Elhammali, A., et al., *A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor*. *Cancer Discov*, 2014. **4**(7): p. 828-39.
193. Matre, P., et al., *Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes*. *Oncotarget*, 2016. **7**(48): p. 79722-79735.
194. Kizilbash, S.H., et al., *A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642)*. *Journal of Clinical Oncology*, 2019. **37**(15_suppl): p. TPS2075-TPS2075.
195. Garrett, M., et al., *Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities*. *Cancer Metab*, 2018. **6**: p. 4.
196. Andronesi, O.C., et al., *Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate*. *Nat Commun*, 2018. **9**(1): p. 1474.
197. McBrayer, S.K., et al., *Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma*. *Cell*, 2018. **175**(1): p. 101-116.e25.
198. Lu, C., et al., *IDH mutation impairs histone demethylation and results in a block to cell differentiation*. *Nature*, 2012. **483**(7390): p. 474-8.

199. Sasaki, M., et al., *IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics*. Nature, 2012. **488**(7413): p. 656-9.
200. Saha, S.K., et al., *Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer*. Nature, 2014. **513**(7516): p. 110-4.
201. Hansen, E., et al., *AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo*. Blood, 2014. **124**(21): p. 3734-3734.
202. Norsworthy, K.J., et al., *FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation*. Clin Cancer Res, 2019. **25**(11): p. 3205-3209.
203. Polychronidou, G., et al., *Novel therapeutic approaches in chondrosarcoma*. Future Oncol, 2017. **13**(7): p. 637-648.
204. Zeidner, J.F., *Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML*. Clin Cancer Res, 2020. **26**(16): p. 4174-4176.
205. Reyhanoglu, G., et al., *Differentiation Syndrome, a Side Effect From the Therapy of Acute Promyelocytic Leukemia*. Cureus, 2020. **12**(12): p. e12042.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.